| Literature DB >> 24405801 |
Abstract
INTRODUCTION: Knowing the repertoire of cell signaling receptors would provide pivotal insight into the developmental and regenerative capabilities of bone marrow cell (BMC)-derived hematopoietic stem/progenitor cells (HSPCs) and bone marrow mesenchymal stromal cells (BMMSCs).Entities:
Mesh:
Substances:
Year: 2013 PMID: 24405801 PMCID: PMC3854681 DOI: 10.1186/scrt323
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 6.832
Figure 1Enrichment of murine bone marrow hematopoietic stem/progenitor (Linc-kitSca-1) cells by fluorescence-activated cell sorting. Lin– bone marrow cells (A) were fluorescence-activated cell sorted for cells expressing high levels of c-kit and Sca-1 (B). Dot plots showing the purity of resorted c-Kit+ CD45+ cells (C) and Sca-1+ c-Kit+ cells (D). Representative results of six independent HSPC cell sorting preparations are shown. FCS, fetal calf serum; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
Figure 2Immunophenotypic characterization of bone marrow mesenchymal stromal cells by flow cytometry (fluorescence-activated cell sorting). Fluorescence-activated cell sorting analysis of cell surface markers illustrating that bone marrow-derived mesenchymal stromal cells (BMMSCs) express known stromal–mesenchymal markers such as CD44, CD73, CD90, CD105, and MHC class I and are negative for the hematopoietic cell lineage markers including CD45, CD11b, CD14, CD34, MHC class II and CD31. Unfilled curve, cells stained with isotype control antibody; filled gray curve, staining against each specific cell surface marker.
Figure 3osteogenic, adipogenic and chondrogenic differentiation of bone marrow mesenchymal stromal cells. Bone marrow-derived mesenchymal stromal cells (BMMSCs; passage 2 to 3) were cultured in vitro under osteogenic, adipogenic and chondrogenic induction condition for 3 weeks. Alizarin Red staining shows mineralization deposition, Oil Red O staining demonstrates the generation of lipid-containing adipocytes and Alcian blue staining demonstrates cartilage matrix (magnification 400). Data shown are representative of six independent experiments.
Differential gene expression between bone marrow-derived hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells
| | | | | | |
| Aatk-apoptosis-associated tyrosine kinase | Mm00545697_m1 | 16.8 ± 0.57 | 17.91 ± 0.30 | 2.5 | 0.009 |
| Axl-AXL receptor tyrosine kinase | Mm00437221_m1 | 21.03 ± 0.41 | 11.49 ± 0.32 | -818.7 | 0.0001 |
| Mertk-c-mer proto-oncogene tyrosine kinase | Mm00434920_m1 | 23.04 ± 0.76 | 18.68 ± 0.41 | -21.7 | 0.0001 |
| Tyro3-TYRO3 protein tyrosine kinase 3 | Mm00444547_m1 | 21.49 ± 0.62 | 15.83 ± 0.38 | -52 | 0.0001 |
| Ddr1-discoidin domain receptor family, member 1 | Mm00432251_m1 | ND | 21.20 ± 0.49 | | |
| Ddr2-discoidin domain receptor family, member 2 | Mm00445615_m1 | ND | 11.46 ± 1.94 | | |
| Egfr-epidermal growth factor receptor | Mm00433023_m1 | 23.44 ± 0.64 | 16.89 ± 0.48 | -88.8 | 0.0001 |
| Epha1-Eph receptor A1 | Mm00445804_m1 | 23.88 ± 0.83 | 20.73 ± 0.42 | -9.2 | 0.0001 |
| Epha2-Eph receptor A2 | Mm00438726_m1 | 19.20 ± 0.96 | 17.34 ± 0.46 | -3.8 | 0.0001 |
| Epha3-Eph receptor A3 | Mm00580743_m1 | ND | 22.18 ± 0.33 | | |
| Epha4-Eph receptor A4 | Mm00433056_m1 | 22.17 ± 0.49 | 20.76 ± 0.41 | -2.8 | 0.0001 |
| Epha6-Eph receptor A6 | Mm00433094_m1 | ND | ND | | |
| Epha7-Eph receptor A7 | Mm00833876_m1 | 22.06 ± 1.10 | 17.57 ± 0.29 | -22.9 | 0.0001 |
| Epha8-Eph receptor A8 | Mm00433106_m1 | ND | ND | | |
| Ephb3-Eph receptor B3 | Mm00802553_m1 | ND | 16.69 ± 0.79 | | |
| Ephb4-Eph receptor B4 | Mm00438750_m1 | 22.21 ± 0.46 | 15.50 ± 0.33 | -107.3 | 0.0001 |
| Fgfr1-fibroblast growth factor receptor 1 | Mm00438923_m1 | 20.91 ± 1.27 | 15.95 ± 0.20 | -36.5 | 0.0001 |
| Fgfr2-fibroblast growth factor receptor 2 | Mm00438941_m1 | ND | 20.55 ± 0.40 | | |
| Fgfr3-fibroblast growth factor receptor 3 | Mm00433294_m1 | ND | 20.32 ± 0.48 | | |
| Insr-insulin receptor | Mm00439693_m1 | 15.97 ± 0.43 | 15.82 ± 0.29 | -1.1 | 0.3273 |
| Met-met proto-oncogene | Mm00434924_m1 | 18.25 ± 0.38 | 14.36 ± 0.49 | -15.9 | 0.0001 |
| Mst1r-macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | Mm00436365_m1 | ND | 24.49 ± 1.08 | | |
| Musk-muscle, skeletal, receptor tyrosine kinase | Mm00448006_m1 | ND | ND | | |
| Csf1r-colony stimulating factor 1 receptor | Mm00432689_m1 | 14.89 ± 0.43 | 22.45 ± 0.43 | 197.3 | 0.0001 |
| Flt3-FMS-like tyrosine kinase 3 | Mm00438996_m1 | 17.68 ± 0.87 | ND | | |
| Kit-kit oncogene | Mm00445212_m1 | 15.21 ± 0.63 | ND | | |
| Pdgfra-platelet derived growth factor receptor, alpha polypeptide | Mm00440701_m1 | ND | 16.71 ± 0.66 | | |
| Pdgfrb-platelet derived growth factor receptor, beta polypeptide | Mm00435546_m1 | 19.98 ± 0.60 | 13.83 ± 0.24 | -72.4 | 0.0001 |
| Ret-ret proto-oncogene | Mm00436304_m1 | 22.27 ± 0.64 | 20.56 ± 0.41 | -3.4 | 0.0001 |
| Ror1-receptor tyrosine kinase-like orphan receptor 1 | Mm00443462_m1 | ND | 18.75 ± 0.37 | | |
| Ror2-receptor tyrosine kinase-like orphan receptor 2 | Mm00443470_m1 | ND | 19.22 ± 0.30 | | |
| Ros1-Ros1 proto-oncogene | Mm00803362_m1 | ND | ND | | |
| Tek-endothelial-specific receptor tyrosine kinase | Mm00443242_m1 | 18.52 ± 1.21 | ND | | |
| Tie1-tyrosine kinase receptor 1 | Mm00441786_m1 | 20.39 ± 0.84 | ND | | |
| Ntrk2-neurotrophic tyrosine kinase, receptor, type 2 | Mm00435422_m1 | ND | ND | | |
| Flt1-FMS-like tyrosine kinase 1 | Mm00438980_m1 | 21.13 ± 0.41 | 20.52 ± 0.49 | -1.6 | 0.0032 |
| Kdr-kinase insert domain protein receptor | Mm00440099_m1 | 23.48 ± 0.60 | 23.31 ± 0.70 | -1.3 | 0.5296 |
| | | | | | |
| Abl1-v-abl Abelson murine leukemia oncogene 1 | Mm00802038_g1 | 16.54 ± 0.54 | 14.93 ± 0.14 | -3 | 0.0001 |
| Tnk1-tyrosine kinase, non-receptor, 1 | Mm00840782_g1 | ND | ND | | |
| Tnk2-tyrosine kinase, non-receptor, 2 | Mm00450301_m1 | 17.25 ± 0.34 | 15.88 ± 0.25 | -2.6 | 0.0001 |
| Matk-megakaryocyte-associated tyrosine kinase | Mm00440268_m1 | 17.49 ± 0.83 | 22.68 ± 0.58 | 41.9 | 0.0001 |
| Ptk2-PTK2 protein tyrosine kinase 2 | Mm00433209_m1 | 20.21 ± 0.90 | 14.67 ± 0.28 | -47.1 | 0.0001 |
| Fert2-fer (fms/fps related) protein kinase, testis specific 2 | Mm00484303_m1 | 17.74 ± 0.48 | 15.11 ± 0.22 | -6.3 | 0.0001 |
| Fes-feline sarcoma oncogene | Mm00802572_g1 | 13.51 ± 0.47 | 17.67 ± 0.45 | 18.8 | 0.0001 |
| Frk-fyn-related kinase | Mm00456656_m1 | ND | 18.56 ± 0.54 | | |
| Srmssrc-related kinase lacking C-terminal regulatory tyrosine | Mm00441546_m1 | ND | ND | | |
| Jak1-Janus kinase 1 | Mm00600614_m1 | 13.23 ± 0.54 | 12.47 ± 0.43 | -1.8 | 0.0009 |
| Jak2-Janus kinase 2 | Mm00434561_m1 | 14.69 ± 0.63 | 15.81 ± 0.25 | 2.4 | 0.0001 |
| Jak3-Janus kinase 3 | Mm00439962_m1 | 16.78 ± 0.62 | 17.93 ± 0.20 | 2.4 | 0.0001 |
| Fgr-Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog | Mm00438949_m1 | 14.67 ± 1.61 | ND | | |
| Fyn-Fyn proto-oncogene | Mm00433373_m1 | 17.01 ± 0.54 | 14.57 ± 0.40 | -5.6 | 0.0001 |
| Hck-hemopoietic cell kinase | Mm00439302_m1 | 14.2 ± 0.76 | 22.11 ± 0.54 | 275.1 | 0.0001 |
| Lck-lymphocyte protein tyrosine kinase | Mm00802897_m1 | 19.42 ± 0.49 | 23.04 ± 0.43 | 13 | 0.0001 |
| Lyn-Yamaguchi sarcoma viral (v-yes-1) oncogene homolog | Mm00802933_m1 | 13.28 ± 0.87 | 19.56 ± 0.51 | 93.1 | 0.0001 |
| Bmx-BMX non-receptor tyrosine kinase | Mm00515368_m1 | 14.73 ± 1.07 | ND | | |
| Btk-Bruton agammaglobulinemia tyrosine kinase | Mm00442712_m1 | 15.05 ± 1.20 | 24.92 ± 0.76 | 972.4 | 0.0001 |
| Tec-cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) | Mm00443230_m1 | 16.2 ± 0.34 | 18.24 ± 0.33 | 4.2 | 0.0001 |
| Txk-TXK tyrosine kinase | Mm00443280_m1 | 20.98 ± 0.50 | ND | | |
| Syk-spleen tyrosine kinase | Mm00441649_m1 | 12.74 ± 0.57 | 17.10 ± 0.21 | 22.1 | 0.0001 |
| Zap70-zeta-chain (TCR) associated protein kinase | Mm00494255_m1 | 19.49 ± 1.30 | ND | | |
| | | | | | |
| Agtrl1-angiotensin receptor-like 1 | Mm00442191_s1 | 19.96 ± 0.56 | 20.22 ± 0.88 | 1.3 | 0.3972 |
| Ednrb-endothelin receptor type B | Mm00432989_m1 | 22.96 ± 1.06 | 22.70 ± 0.67 | -1 | 0.4802 |
| Ccr1-chemokine (C-C motif) receptor 1 | Mm00438260_s1 | 13.33 ± 0.63 | 19.78 ± 1.13 | 95.6 | 0.0001 |
| Ccr3-chemokine (C-C motif) receptor 3 | Mm00515543_s1 | 19.93 ± 0.36 | 20.03 ± 1.10 | 1.1 | 0.7675 |
| Ccr4-chemokine (C-C motif) receptor 4 | Mm00438271_m1 | 23.9 ± 1.24 | ND | | |
| Ccr7-chemokine (C-C motif) receptor 7 | Mm00432608_m1 | 18.32 ± 1.50 | ND | | |
| Ccr8-chemokine (C-C motif) receptor 8 | Mm00843415_s1 | 21.55 ± 0.44 | 19.71 ± 0.83 | -4.1 | 0.0001 |
| Cxcr3-chemokine (C-X-C motif) receptor 3 | Mm00438259_m1 | 20.74 ± 0.36 | ND | | |
| Blr1 (Cxcr5)-Burkitt lymphoma receptor 1 | Mm00432086_m1 | 20.88 ± 1.00 | ND | | |
| Cmkor1 (Cxcr7)-chemokine orphan receptor 1 | Mm00432610_m1 | 23.68 ± 1.01 | 15.52 ± 0.35 | -293.2 | 0.0001 |
| | | | | | |
| Acvr1-activin A receptor, type 1 | Mm00431645_m1 | 17.98 ± 0.83 | 13.57 ± 0.45 | -22.2 | 0.0001 |
| Acvrl1-activin A receptor, type II-like 1 | Mm00437432_m1 | 20.73 ± 0.60 | 19.32 ± 0.67 | -2.9 | 0.0001 |
| Bmpr1a-bone morphogenetic protein receptor, type 1A | Mm00477650_m1 | 17.28 ± 0.95 | 14.75 ± 0.22 | -5.9 | 0.0001 |
| Il3ra-interleukin 3 receptor, alpha chain | Mm00434273_m1 | 18.52 ± 0.53 | 18.40 ± 0.44 | -1.1 | 0.5524 |
| Il6ra-interleukin 6 receptor, alpha | Mm00439653_m1 | 14.54 ± 0.38 | 16.40 ± 0.51 | 3.8 | 0.0001 |
| Il7r-interleukin 7 receptor | Mm00434295_m1 | 17.11 ± 0.24 | 24.38 ± 0.75 | 155.9 | 0.0001 |
| Csf2ra-colony stimulating factor 2 receptor, alpha | Mm00438331_g1 | 14.46 ± 0.40 | 19.04 ± 0.22 | 24.9 | 0.0001 |
| Csf2rb2-colony stimulating factor 2 receptor, beta 2 | Mm00655763_m1 | 17.33 ± 0.38 | ND | | |
| Csf3r-colony stimulating factor 3 receptor | Mm00432735_m1 | 11.85 ± 1.43 | ND | | |
| Epor-erythropoietin receptor | Mm00833882_m1 | 19.42 ± 1.07 | 22.59 ± 0.85 | 11.6 | 0.0001 |
| Lifr-leukemia inhibitory factor receptor | Mm00442940_m1 | 17.89 ± 0.64 | 16.76 ± 0.36 | -2.3 | 0.0001 |
| Mpl-myeloproliferative leukemia virus oncogene | Mm00440310_m1 | 14.86 ± 1.69 | ND | | |
| Ngfr-nerve growth factor receptor (TNFR superfamily, member 16) | Mm00446294_m1 | ND | 11.96 ± 0.30 | | |
| Osmr-oncostatin M receptor | Mm00495424_m1 | ND | 15.97 ± 0.24 | | |
| Tnfrsf1a-tumor necrosis factor receptor superfamily, member 1a | Mm00441875_m1 | 13.49 ± 0.36 | 13.91 ± 0.24 | 1.4 | 0.0023 |
| | | | | | |
| Abcb1b-ATP-binding cassette, sub-family B (MDR/TAP), member1B | Mm00440736_m1 | 18.64 ± 0.64 | 17.73 ± 0.38 | -1.9 | 0.0003 |
| Mrc1-mannose receptor, C type 1 | Mm00485148_m1 | 20.76 ± 0.47 | 22.00 ± 0.62 | 2.5 | 0.0001 |
| Gata4-GATA binding protein 4 | Mm00484689_m1 | ND | 20.10 ± 0.31 | | |
| Hoxb4-homeo box B4 | Mm00657964_m1 | 17.88 ± 0.50 | 17.28 ± 0.59 | -1.7 | 0.0134 |
| Ptprc-protein tyrosine phosphatase, receptor type, C | Mm00448463_m1 | ND | ND | | |
| Gas6-growth arrest specific 6 | Mm00490378_m1 | 23.45 ± 1.02 | 14.90 ± 0.26 | -381.1 | 0.0001 |
| Lgals9-lectin, galactose binding, soluble 9 | Mm00495295_m1 | 13.67 ± 0.82 | 17.69 ± 0.25 | 18.9 | 0.0001 |
| Sca1-spinocerebellar ataxia 1 homolog (human) | Mm00485928_m1 | 17.08 ± 0.23 | 15.71 ± 0.29 | -2.6 | 0.0001 |
| Spp1-secreted phosphoprotein 1 | Mm00436767_m1 | 17.91 ± 0.33 | 9.23 ± 0.44 | -424.9 | 0.0001 |
Gene differential expression was considered significant with P <0.05. Mean ± standard deviation of six independent HSPC and BMMSC preparations are shown. BMMSC, bone marrow-derived mesenchymal stromal cell; Ct, cycle threshold; HPSC, hematopoietic stem/progenitor cell; ND, not detectable; RTK, receptor tyrosine kinase. aQuantitative PCR was performed on an ABI PRISM 7900HT Sequence Detection System using a custom-made TaqMan® Low Density Array. mRNA transcripts were evaluated with TaqMan® Probes commercially available as Assay on Demand (Applied Biosystems, Foster City, CA, USA) with optimized primer and probe concentrations.
bMean ± standard deviation mRNA level of each gene in each cell population (six individual cell samples run in duplicate) were first normalized to the expression of 18S RNA in that sample.
cMean fold-changes in gene transcript expression levels between HSPCs and BMMSCs were evaluated with 2–ΔΔCt.
Figure 4Cell surface protein expression on undifferentiated hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells. Cell surface expression of CD45, cKit, Sca-1, Kdr (Flk1/Vegfr2), Ddr2 and Pdgfra on undifferentiated Lin–c-Kit+Sca-1+ cells (hematopoietic stem/progenitor cells (HSPCs)) and bone marrow-derived mesenchymal stromal cell (BMMSCs; passage 2) via flow cytometric analysis. Unfilled curve, cells stained with isotype control antibody; filled gray curve, staining against each specific protein.